|October 7, 2013|
|08:05 EDT||NPSP||NPS Pharmaceuticals says study findings confirm potential of Natpara |
NPS Pharmaceuticals announced that its pivotal Phase 3 study of Natpara, known as REPLACE, was published online in The Lancet Diabetes & Endocrinology. Study findings underscore Natpara’s potential as a replacement therapy for endogenous parathyroid hormone in hypoparathyroidism, a rare endocrine disorder characterized by insufficient production of PTH. 53% of Natpara-treated patients achieved the primary endpoint by decreasing doses of oral calcium and active vitamin D by 50 percent or more, while maintaining serum calcium levels by the end of the treatment phase. In contrast, only 2% of the placebo group met the primary endpoint. NPS expects to submit its Biologic License Application to the U.S. Food and Drug Administration for the treatment of hypoparathyroidism in the fourth quarter of 2013.
News For NPSP From The Last 14 Days
Check below for free stories on NPSP the last two weeks.
|December 11, 2013|
|07:35 EDT||NPSP||Elsevier Business Intelligence to hold a summit|
Subscribe for More Information
|December 10, 2013|
|07:41 EDT||NPSP||Oppenheimer to hold a conference|
24th Annual Healthcare Conference is being held in New York on December 10-11.
|December 3, 2013|
|14:39 EDT||NPSP||NPS Pharmaceuticals weakness attributed to comments on Natpara|
NPS Pharmaceuticals management said at a conference hosted by Deutshce Bank that it does not know if an FDA panel will be need for Natpara, according to Bloomberg. The company said it doesn't expect a priority review for Natpara, the news service added. Shares of NPS have fallen to session lows, down 7.7% to $24.04.
|07:09 EDT||NPSP||Deutsche Bank to host a conference|
BioFest is being held in Boston on December 2-3 with webcasted company presentations to begin on December 3 at 7:50 am; not all company presentations may be webcasted. Webcast Link
|December 2, 2013|
|12:34 EDT||NPSP||NPS Pharmaceuticals to hold an investor and analyst meeting|
Investor and Analyst Meeting is being held in New York on December 6 at 8:30 am. Webcast Link